ClinicalTrials.gg
Sign In

Drug

Anti-CTLA-4 Monoclonal Antibody SHR-8068 clinical trials

Also written SHR-8068.

studies test it
15
open now
12
in phase 3
4
first study started
2022

Keep track of what changes. Save the Anti-CTLA-4 Monoclonal Antibody SHR-8068 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SHR-8068 Injection
3

Development codes

SHR-8068
8

Combined with it in one product

SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
1
SHR-8068 + Adebrelimab + Bevacizumab
1
Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin
1

Studies by the year they started

15 studies that test it; most in 2024 (7)

Studies that test Anti-CTLA-4 Monoclonal Antibody SHR-8068, by start year
YearStudies
20221
20247
20251
20266

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
11
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Stomach Neoplasms
1

Who runs them

Industry 11 · Other 4

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (9) · The Affiliated Hospital of Qingdao University (1) · Fudan University (1) · Shanghai Zhongshan Hospital (1) · West China Hospital (1) · Shanghai Shengdi Pharmaceutical Co., Ltd (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)

Often tested with

Tested in the same studies.

Adebrelimab (5) · Bevacizumab (3) · Oxaliplatin (1) · Capecitabine (1) · Paclitaxel (1) · Cisplatin (1) · SHR-1701 (1) · Xelox (1)

Studies

Open first, then newest update. How each study uses Anti-CTLA-4 Monoclonal Antibody SHR-8068 is read from its arms, and is right about nine times in ten.

Testing it · 15

Given in every arm · 7 — Anti-CTLA-4 Monoclonal Antibody SHR-8068 is usual care beside what is tested